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Summary Podoplanin is a mucin-type glycoprotein firstly identified in podocytes, which is
homologous to the type I alveolar cell specific T1a-2 antigen and to the oncofetal antigen
M2A recognized by the D2-40 antibody. Podoplanin possesses a platelet aggregation-stimulating
domain causes the platelet aggregation on cancer cells by the binding activity to CLEC-2.
Podoplanin also contributes to the formation of membrane-actin structures. The increased
podoplanin expression is found in squamous cell carcinomas at the invasive edge. It has been
reported that the podoplanin induces an actin cytoskeleton rearrangement dependent on the
RhoA GTPase activation to phosphorylate ezrin and facilitates an epithelial-mesenchymal transi-
tion (EMT) which induces the single cell migration of cancer cells. However, the podoplanin-
expressing cancer cells often express E-cadherin and migrate in a collective manner, suggesting
that there are podoplanin-induced alternative pathways for the actin cytoskeleton rearrangement
independent of the RhoA activation and EMT. The strong expression of podoplanin is present
in salivary gland myoepithelial cells, and in enamel epithelia and odontoblasts of the tooth
germ for a bell stage. Podoplanin may act as a cell morphological regulator in normal and
cancer cells.
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166 Y. Sawa1. Expression of podoplanin in the human
somatic tissue
1.1. Roles of podoplanin as a podocyte antigen
Podoplanin, also called as E11 antigen/GP36/aggrus, is a
mucin-type 38-kDa transmembrane glycoprotein firstly iden-
tified as a 43-kd protein of the kidney glomerular epithelial
cells, podocytes [1]. Podoplanin is homologous to T1a-2 gene
which encodes the type I alveolar cell specific antigen and to
the oncofetal antigen M2A recognized by the D2-40 antibody
[2—4]. The role of podoplanin has been studied in a rat model
of nephropathy by the puromycin aminonucleoside nephrosis
with severe proteinuria. In the kidney with nephropathy,
podocyte foot processes are extensive flattening and podo-
planin is selectively reduced to <30%. It has been thought
that podoplanin plays a role in maintaining the shape of
podocyte foot processes and glomerular permeability
because of morphological alterations of cell shape with
selective loss of podoplanin in the nephrosis accompanies
proteinuria [1,5—7].
1.2. Lymphatic endothelial cell marker,
podoplanin
The study for the lymphatic systemat amolecular biology level
made rapid progress greatly since 1999 when much break-
through about lymphatic endothelial cell markers, such as
desmoplakin, LYVE-1, Prox1, and podoplanin, has been accom-
plished [8—11]. The discovery most major in these would be
that lymphatic development is independent of the vascular
system development, and that lymphatic-specific homeobox
gene Prox1 induces the lymphatic endothelial development
from embryonic veins and homozygous Prox1-null mouse
embryos die because of multiple developmental defects
[11—15]. Prox1 is amaster regulator of the podoplanin expres-
sion induced with epidermal growth factor, basic fibroblast
growth factor, tumor necrosis factor alpha, interleukin-3, and
transforming growth factor beta. Prox1 enables to reprogram
vascular endothelial cells to become podoplanin-expressing
lymphatic endothelial cells [13—16]. It has been firstly
reported that podoplanin is predominantly expressed by lym-
phatic endothelium in angiosarcomas mixed endothelial phe-
notypes of blood and lymphatic capillaries [8]. Podoplanin is
first expressed at around E11.0 in Prox1-positive lymphatic
progenitor cells [10]. Podoplanin(/) mice die at birth
because of the respiratory failure and have defects in lym-
phatic formation with diminished lymphatic transport, con-
genital lymphedema and dilation of lymphatic vessels, but not
have defects in blood vessel pattern formation. Podoplanin
promotes lymphatic endothelial cell adhesion and regulates
the lymphatic vasculature formation [10]. The immunoelec-
tron microscopic study has demonstrated that podoplanin is
expressed on the luminal side of lymphatic vessels and rarely
on the basal side [17]. The podoplanin and Prox1 expression isregulated by IL-3 which expressed in lymphatic but not blood
endothelium. The endogenous IL-3 is required to maintain the
lymphatic endothelial cell phenotype and appears to induce
transdifferentiation of blood endothelium into lymphatic
endothelium [16]. Furthermore, recent study showed that
the early activation of a Ras homolog gene family, member
A (RhoA)-GTPase in the lymphangiogenic process, which is
required for the successful establishment of the capillary
network, is dependent on podoplanin expression [18]. In the
study for the response of lymphatic vascular systems against
the infection, we have been reported that lymphatic endothe-
lium significantly increases podoplanin expression with lipo-
polysaccharide and lipoteichoic acid by the recognition
mechanisms to pathogen-associated molecular patterns
through toll-like receptors [19—21].
1.3. Podoplanin expression in the oral and other
tissues
In the oral tissue the expression of podoplanin is weakly found
in mucous epithelial cells at a basal layer and strongly in
myoepithelial cells of salivary glands [22] (Fig. 1). The podo-
planin expression is rarely found in acini of the parotid gland
but clearly found at the basal portion of acini in the subman-
dibular and sublingual glands. The strong expression of podo-
planin is also found at the basal portion of the intercalated
duct, striated duct and interlobular duct in all major salivary
glands. In the parotid gland few myoepithelial cells are on the
terminal portion while in the sublingual gland and subman-
dibular gland, approximately 50% and 25% of the terminal
portion surface are covered by myoepithelial cells with a
number of broad and extensive cellular processes. Myoepithe-
lial cells actasa contractile cell for the saliva secretionand the
cell shape varies considerably with the different glands in
relation to the physical properties of secretions [23]. Podo-
planin would be amarker protein of salivary glandmyoepithe-
lial cells because the podoplanin detection levels coincide
with the distribution and the cell shape of myoepithelial cells
specific formajor salivary glands.Podoplaninmayplay a role in
maintaining the shape of myoepithelial cell foot processes to
press acinar cells from the outside.
The podoplanin expression is also found in the tooth germ
tissue [24] (Fig. 2). The expression is strongly found in inner
and outer enamel epithelia at the early bell stage while
rarely in the enamel organ at the crown stage. Furthermore,
the podoplanin expression is rarely found in themesenchymal
cells of dental papilla except for odontoblasts. The strong
expression of podoplanin in odontoblasts is sustained during a
dentin formative period and diminished at the root formation
stage. It has been reported that podoplanin promotes the
plasma membrane extension and the actin cytoskeleton
rearrangement involved in cell mobility [25—27]. Podoplanin
may be involved in the cell shape formation of odontoblasts
and in the migration of epithelial cells into mesenchymal
cells like cancer cells.
Figure 1 Podoplanin expression in the mouse oral tissues. (A and D) Serial sections of the tongue tissue. Reaction products of anti-
podoplanin with green fluorescence are found in the mucosal epithelial cells at a basal layer (asterisk), myoepithelial cells of lingual
glands (arrowheads), and lymphatic vessels (arrow). (B and E) Serial sections of parotid gland. Podoplanin expression is rarely found in
the terminal secretory end pieces of acini composed of serous pyramidal cells but clearly found in the striated and intercalated ducts
(SD, IC) composed of columnar cells with acidopillic cytoplasm. (C and F) Serial sections of sublingual gland. Podoplanin expression is
clearly found in terminal secretory end pieces composed of mucous-filled acinar cells and in the intercalated ducts (IC) having a narrow
lumen surrounded by cuboidal cells. Bar, 0.1 mm.
Figure 2 Podoplanin expression in the mouse tooth germ tissue. (A and D) Serial sections of the molar tooth germ at the bell stage.
Reaction products of anti-podoplanin with green fluorescence are observed in the cervical loops where the outer and inner enamel
epithelia join at apical sides of the tooth germ (arrowheads), and in the odontoblast layer (arrow). The podoplanin expression is partially
weakly found in the enamel organ containing ameloblasts (asterisk) but not found in the mesenchymal cells of dental papilla except for
odontoblasts. (B andE) Cervical loop.Highermagnification of (a). Reaction productswith anti-podoplanin are observed strongly at plasma
membrane of inner and outer enamel epithelia (arrowheads) and in odontoblasts (arrow). The podoplanin expression is not found in the
mesenchymal cells of dental papilla (asterisk). (C and F) Odontoblast layer. Higher magnification of (b). Reaction products with anti-
podoplanin are observed strongly at plasma membrane in odontoblasts (arrow) but not in the mesenchymal cells of dental papilla. The
podoplanin expression is weakly found in the enamel organ containing ameloblasts (asterisk). Bar, 0.1 mm.
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in osteocytes and osteoblasts [28], mesothelial cells [4,29],
epidermal basal layer cells [4,10], choroid plexus epithelial
cells, thymus type I epithelial cells, myoepithelial cells,
prostate myofibroblasts, follicular dendritic cells, and imma-
ture cells like fetal germ cells and developing Sertoli cells
[1,4,10,29—34]. Elucidation of the common biological impor-
tance in these somatic tissues is required.
2. Expression of podoplanin in cancer
Podoplanin up-regulation has been reported in squamous cell
carcinomas of the skin, lung, esophagus, cervix, larynx and
oral cavity whereas very low levels or a complete absence of
podoplanin protein is found in cell lines and adenocarcinomas
[35,36,33]. There are reports about the podoplanin expres-
sion directed to two different biological significances for
tumor aggressiveness. In generative organs, the expression
of podoplanin as an immunohistochemical marker to cancer
has been firstly reported for seminoma of which about 90%
are podoplanin positive [37—39]. Podoplanin is highly
expressed in primary and metastatic seminoma. In testicular
germ-cell tumors of young adults derived from a pre-invasive
intratubular lesion, carcinoma in situ, podoplanin over-
expresses in the tumors compared to the normal adult testis
[11]. Podoplanin is also strongly expressed by granulosa cells
in normal ovarian follicles, and by ovarian dysgerminomas
and granulosa cell tumors [4,11]. In brain tumors, podoplanin
expression is correlated to malignancy and the expression
extremely occurs in a high rate in pilocytic astrocytomas,
glioblastomas, and germinomas. Podoplanin expression is
markedly higher in glioblastomas than in anaplastic astro-
cytomas [40—42]. It is also reported that podoplanin expres-
sion is strongly induced in epidermal squamous cell
carcinomas because podoplanin is the fos target gene in skin
carcinogenesis [43]. Podoplanin expression extremely occurs
in a high rate in epithelioid mesotheliomas [44—47]. In oral
squamous cell carcinomas, podoplanin expression is present
in about 50% tumors at the invasive front. The 60% of oral
tongue cancers express high levels of podoplanin and the
patients have a statistically significantly higher rate of lymph
node metastasis. Patients with lymph node metastasis and
high-level podoplanin show the shortest disease-specific sur-
vival than other patients. Furthermore, podoplanin fre-
quently expresses in oral leukoplakia which is a
heterogeneous oral lesion with an increased oral cancer risk.
These reports may suggest that podoplanin is involved in oral
tumorigenesis and serves as a predictor for the risk for oral
cancer development, lymph node metastasis and poor clin-
ical outcome [48—50].
It appears that podoplanin plays a tumor biological role in
not only cancer cells but also cancer-associated fibroblasts.
There are two different reports about significances of podo-
planin expression in cancer-associated fibroblasts. One sug-
gests that podoplanin expression in cancer-associated
fibroblasts is associated with poor prognosis for the lung
adenocarcinoma [51]. The other suggests that podoplanin
expression in stromal fibroblasts could have a protective role
against colorectal carcinoma cell invasion and is a significant
indicator of a good prognosis in patients with advanced
colorectal carcinoma. It is supported by biological analysisshowing that podoplanin expression in cancer-associated
fibroblasts is associated with decreased colorectal carcinoma
cell invasion [52]. Furthermore, over-expression of podopla-
nin in 66% of squamous cell carcinoma of the lung is reported
[53]. The expression may reflect the most immature status in
the differentiation process of lung squamous cell carcinoma
with lower biological aggressiveness because patients with
podoplanin-positive tumors resulted in significantly better
survival than those with podoplanin-negative tumors [54]. It
must be elucidated why the biological significances of podo-
planin expression in cancer and cancer-associated fibroblasts
are directed to two contradictory prognosis factors.
3. Molecular characteristics of podoplanin
3.1. Transcription of podoplanin gene
Podoplanin consists of 162 amino acids with 9 amino acids of
extracellular domain, and is regulated with the gene con-
structed by 34.2 kbp with 8 exons and four transcript variants
[9]. It has been reported that epidermal growth factor, basic
fibroblast growth factor and tumor necrosis factor could
induce podoplanin expression in MCF7 breast cancer cells
[25,33,55], and transforming growth factor-beta induces the
expression in human fibrosarcoma [56]. Podoplanin transcrip-
tion enhances in cells having a chromatin with strongly
methylated CpG sites at the promoter region of podoplanin
gene. Putative binding sites for transcription factor AP-2, AP-
4, C/EBP, and NF-1 exist in podoplanin promoter sequence
[57]. The podoplanin gene 50 flanking region lacks a consensus
TATA box whereas a GATA box (GATAAA) is localized 31
nucleotides upstream of the main mRNA transcription initia-
tion site. The podoplanin gene 50-flanking region has a high
GC content and revealed the existence of several potential
Sp1 transcription factor sites. Sp1 and Sp3 occupy the same or
overlapping sites of the podoplanin promoter because Sp1
and Sp3 are not bound coordinately to the DNA stretches.
Over-expressions of Sp1 and Sp3 independently increase
podoplanin transcription in human osteoblastic osteosar-
coma cell line MG63 and osteosarcoma cell line Saos-2 which
insufficiently recruits nuclear Sp for transcriptional activa-
tion, and the promoter controlling podoplanin transcription
in MG63 exhibits 30-fold more activity than in Saos-2. The
MG63 cell has a chromatin with strongly methylated CpG sites
at a 464 bp upstream of the distal promoter region of podo-
planin gene but the same sites of Saos-2 cell chromatin are
hypomethylated, and a treatment with the DNA methyltrans-
ferase inhibitor 5-azaCdR in combination with trichostatin A
results in the transcriptional downregulation of podoplanin
mRNA in MG63 cells. These suggest that the highly methyla-
tion of chromatin at the promoter region of podoplanin gene
aids to the cell-type specific up-regulation of podoplanin
gene transcriptional activity [57].
3.2. Molecular biological function of podoplanin
Podoplanin is a mucin-type glycoprotein negatively charged
by extensive O-glycosylation and is a high content of sialic
acid [57,58]. About the molecular biological characterization
of podoplanin there are detailed studies by Kato and co-
workers [58,59]. The C-type lectin-like receptor CLEC-2
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platelet aggregation on cancer cells without blood coagula-
tion factors and plasma components. Podoplanin consists of
an extracellular domain having rich serine and threonine
residues, a transmembrane domain, and a cytoplasmic tail
for protein kinase C and cAMP phosphorylation [59,60].
Podoplanin possesses a platelet aggregation-stimulating
(PLAG) domain (EDDVVTPG) in an extracellular domain. In
the PLAG domain only the Thr52 is O-glycosylated with
disialyl-core1 (NeuAc-a2-3Galb1-3 (NeuAca2-6) GalNAca1-
O-Thr) to induce platelet aggregation and the mutation of
threonine residues in the PLAG domain reduces the platelet
aggregation. The binding of podoplanin to the specific recep-
tor CLEC-2 is dependent on sialic acid on O-glycans in the
PLAG domain by the lectin activity and plays a key role for the
platelet aggregation (Fig. 3). It is thought that the interac-
tion between podoplanin and CLEC-2 is one of the factor
regulates tumor invasion and metastasis because both the
platelet aggregation and lung metastasis of mouse colon
carcinoma are inhibited by 8F11 monoclonal antibody for
podoplanin [53,58—62]. There are three tandem repeats of
the PLAG domain which are conserved in podoplanin homo-
logues from rat, hamster, dog, bovine, human and mouse.
The podoplanin homologues conserve the segment of
EDxxVTPG in the extracellular domains critical for their
platelet aggregation-inducing activities. Either the first or
last PLAG domain is critical for the platelet aggregation-
inducing activity. Bovine podoplanin has a sporadic deletion
mutation in the first PLAG domain and lacks platelet aggre-Figure 3 Podoplanin-induced actin cytoskeleton re-arrange-
ment. Podoplanin induces the activation of a RAS homolog gene
family, member A (RhoA) GTPase and a Rho-associated coiled
coil-containing protein kinase 1 (ROCK1) to phosphorylate ezrin.
Phospholyrated ezrin acts as a cytoplasmic linker protein, which
intermediately connects F-actin to membrane proteins including
podoplanin, and develops membrane-actin structures at the cell-
surface. Podoplanin directly binds to phospholyrated ezrin at the
cytoplasmic tail and indirectly promotes an actin cytoskeleton
re-arrangement by stabilizing the phosphorylated ezrin mediat-
ing an anchorage of F-actin to the plasma membrane.gation-inducing activity [62,63]. The podoplanin is a main
factor for platelet aggregation induced by the glioblastoma
cell line LN319 and a NZ-1 antibody for the PLAG domain
completely inhibits podoplanin-induced platelet aggregation
because of the neutralization between podoplanin and CLEC-
2 [58,61]. In an experimental mouse model podoplanin pro-
moted hematogenous metastasis to the lung and the anti-
podoplanin antibody NZ-1 suppressed both the podoplanin-
CELC-2 interaction and podoplanin-induced pulmonary
metastasis [59,61,64,65]. Possibility of the clinical applica-
tion on the neutralization of podoplanin-CLEC-2 interaction
inducing hematogenous metastasis should be settled early.
3.3. Novel aspects on the event podoplanin
induces in cancer cells: EMT or not?
Analysis of cancer cell migration and invasion mechanisms
caused by podoplanin expression is directed to two contra-
dictory reports although both reports accord about the role of
podoplanin which mediates remodeling of the actin cytoske-
leton. One suggests that podoplanin induces an actin cytos-
keleton rearrangement by epithelial-mesenchymal transition
(EMT) based on the binding activity with plasma membrane
protein ERM: ezrin, radixin and moesin to activate RhoA [27].
The other suggests that podoplanin-induced migration and
invasion could occur in the absence of EMT because of neither
ERM up-regulation nor E-cadherin down-regulation in podo-
planin-positive cancer [55]. In fact, some cancer cell migra-
tion and invasion depend on an active remodelling of the
actin cytoskeleton linked with membrane proteins via ERM
[66] (Fig. 1). Ezrin is a cytoplasmic linker protein which is
expressed in epithelial cell surface structures like microvilli
but not usually in mesenchymal cells [67]. Ezrin with the
phosphorylated tyrosine (pTyr)-353 protects epithelial cells
against apoptosis and determines cell survival by activating
the phosphatidylinositol 3-kinase (PI3-kinase)/Akt pathway
because the pTyr-353 residue binds to the regulatory subunit
of PI3-kinase. Ezrin-actin binding is required for the receptor
tyrosine kinase signal transfer to the Ras/MAP kinase signal-
ling pathway and functions in the development ofmembrane-
actin structures critical for cell shape and motility [68—70].
Podoplanin co-localizes with ERM at actin-rich microvilli and
the podoplanin over-expression in MCF7 cells, MDCK cells,
and HaCaT keratinocytes leads to a marked increase in
phosphorylation of ezrin [25,27,48]. Podoplanin directly
binds to ezrin at three basic residue RKR in the cytoplasmic
tail amino acid RKMSGRYSP and up-regulates a Ras homolog
gene family, member A (RhoA)-GTPase activity resulting in
the ezrin phosphorylation by Rho-associated coiled coil-con-
taining protein kinase 1 (ROCK1) [27]. The increased cell-
surface distribution of phosphorylated ezrin promotes the
actin cytoskeleton rearrangement by the development of
membrane-actin structures because phosphorylated ezrin
is a cytoplasmic linker protein intermediating the connection
of membrane proteins at the NH2-terminal domain and F-
actin at the COOH-terminal domain. Therefore, podoplanin
indirectly promotes an actin cytoskeleton rearrangement by
the RhoA activation. Furthermore, podoplanin binds to phos-
pholyrated ezrin at the cytoplasmic tail and directly pro-
motes the stabilization of the phosphorylated ezrin
mediating an anchorage of F-actin to the plasma membrane.
170 Y. SawaSuch a series of events in podoplanin-positive cancer cells
may facilitate EMT which plays a role for the plasma mem-
brane extension of epithelial cell surface structures like
microvilli, and for the cancer cell migration and invasion
[25—27].
The cadherin switch is one of the EMT events in the
transition from adenoma to carcinoma and some carcinomas
correlate with EMT based on the down-regulation of the cell—
cell adhesion protein E-cadherin [71,72]. It is necessary to
lose E-cadherin expression and express N-cadherin instead at
the progression from adenoma to carcinoma in the well-
studied multistep tumor progression model of the Rip1Tag2
mouse pancreatic beta-cell carcinogenesis [73]. However,
the forced podoplanin expression in beta-cell tumors of
Rip1Tag2 mice induces the carcinoma formation without
EMT and no ERM up-regulation occurs in podoplanin-positive
cancer [55]. Furthermore, the podoplanin-expressing cancer
cells often express E-cadherin even in advanced stages and
the cancer cells tend to migrate in a collective manner. It
seems that podoplanin could induce an actin cytoskeleton
rearrangement independent of the RhoA activation and pro-
mote the invasion activity without a cadherin switch [55].
In squamous cell carcinoma, the podoplanin expression is
frequently restricted to the invasive front and in stem cell
marker CD44 and p63 positive tumor cells less than 50%
simultaneously expresses podoplanin. Podoplanin-positive
cells are localized more peripherally in the tumor nests than
CD44 and p63 positive cells, showing that tumor cells are
aligned in the hierarchical distribution pattern. Patients
having podoplanin-positive tumors with the hierarchical pat-
tern resulted in significantly better survival than those having
podoplanin-negative tumors. The three hierarchical expres-
sions of podoplanin, CD44 and p63 in the squamous cell
carcinoma may reflect the most immature status of tumor
with lower biological aggressiveness [54]. The human squa-
mous cell carcinoma cell line A431 contains podoplanin-
positive cells which generate podoplanin positive and nega-
tive cells [74]. Podoplanin-negative cells rarely generate
podoplanin-positive cells. Furthermore, podoplanin positive
A431 cells share sonic hedgehog and CD44 expression with
stem cells in normal squamous epithelium. These studies may
suggest the role of podoplanin as a candidate of tumor-
initiating cell marker in squamous cell carcinoma. The elu-
cidation about tumor biological significance of podoplanin
should be dependent on the kinetics with modular proteins to
podoplanin.
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